Tenet Healthcare
THC
$196.60
+1.87%
Tenet Healthcare Corporation is a major healthcare services organization operating a network of acute and specialty hospitals, ambulatory surgery centers, and outpatient facilities across the United States, primarily in the South. The company is a significant player in the Medical - Care Facilities industry, also providing revenue cycle management solutions through its Conifer segment. The current investor narrative is focused on the company's solid operational execution and financial discipline, as evidenced by recent quarterly results showing revenue growth and profitability, though the stock has experienced significant volatility and a sharp pullback from recent highs, reflecting market concerns over broader healthcare sector pressures and valuation adjustments.…
THC
Tenet Healthcare
$196.60
Investment Opinion: Should I buy THC Today?
Rating & Thesis: The synthesized recommendation is Hold. The core thesis is that while THC possesses strong fundamental cash flows and reasonable valuation, these are currently offset by high financial leverage, significant technical weakness, and sector headwinds, warranting a cautious stance until the price stabilizes or the balance sheet improves.
Supporting Evidence: The Hold rating is supported by several data points: 1) a reasonable forward P/E of 11.12x, 2) robust TTM free cash flow of $2.53 billion, 3) consistent revenue growth of nearly 9% YoY, and 4) a solid current ratio of 1.76 indicating adequate short-term liquidity. However, the high debt-to-equity of 3.12 and the stock's severe recent underperformance (-16.77% in one month) counterbalance these positives.
Risks & Conditions: The two biggest risks are a further de-rating due to its high beta and volatility, and an inability to reduce leverage meaningfully. This Hold would upgrade to a Buy if the stock finds durable support above $188 and the company demonstrates a clear path to reducing its debt-to-equity ratio below 2.5. It would downgrade to a Sell if quarterly revenue growth decelerates below 5% or if the stock breaks below the $188 support level decisively. Based on its current multiples relative to its own history, the stock appears fairly valued, neither offering a clear margin of safety nor trading at an excessive premium.
Sign up to view all
THC 12-Month Price Forecast
The outlook for THC is one of high uncertainty balanced by fundamental strength. The company's powerful cash engine is its greatest asset, but it is currently trapped in a stock plagued by leverage concerns and negative momentum. The most likely path (Base Case, 60% probability) is a volatile, range-bound trade as the market digests these cross-currents. The stance is neutral due to the offsetting forces; confidence is only medium due to the limited analyst coverage and high volatility. The stance would upgrade to bullish on evidence of sustained debt reduction and technical stabilization above $215. It would turn bearish on a breakdown below $188 coupled with a deterioration in quarterly cash flow.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Tenet Healthcare's 12-month outlook, with a consensus price target around $255.58 and implied upside of +30.0% versus the current price.
Average Target
$255.58
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$157 - $256
Analyst target range
Insufficient analyst coverage data is available to form a consensus view; the provided data includes only three analysts for earnings and revenue estimates, with no explicit price targets, recommendation distribution, or average target price listed. This limited coverage typically indicates the stock is a mid-cap name with selective institutional interest, which can lead to higher volatility and less efficient price discovery compared to heavily covered large-cap peers. The recent institutional ratings from firms like Guggenheim, Mizuho, and Barclays in February and March 2026 are uniformly positive (Buy/Outperform/Overweight), suggesting a bullish sentiment among the covering analysts, but without quantified targets, the implied upside or conviction level cannot be determined.
Bulls vs Bears: THC Investment Factors
The evidence presents a balanced but tense picture. Bullish arguments are grounded in solid fundamentals: strong cash flow, reasonable valuation, and steady profitability. Bearish concerns are equally compelling, focusing on high leverage, severe technical deterioration, and sector-wide pressures. Currently, the bear side has stronger near-term evidence due to the stock's sharp 17% one-month decline and high beta, which suggests the market is prioritizing risk-off sentiment and sector rotation over the company's stable financials. The single most important tension in the investment debate is whether THC's robust free cash flow and operational execution can overcome its significant financial leverage and the broader market's negative re-rating of healthcare services stocks. The resolution of this tension—specifically, whether the company can de-lever without sacrificing growth while the sector stabilizes—will determine the stock's direction.
Bullish
- Strong Free Cash Flow Generation: The company generated $2.53 billion in TTM free cash flow, providing significant internal funding for debt reduction and growth initiatives. This robust cash generation underpins financial flexibility and operational resilience.
- Attractive Valuation Multiples: THC trades at a forward P/E of 11.12x and an EV/EBITDA of 6.59x, which are reasonable for a profitable healthcare services company. The P/S ratio of 0.85x suggests the market is not overpaying for its revenue base.
- Solid Profitability and Margins: Q4 2025 net income was $371 million with a net margin of 6.70%, supported by a gross margin of 41.52%. This demonstrates consistent earnings power across recent quarters, with net income ranging from $288M to $406M.
- Positive Revenue Growth Trajectory: Q4 2025 revenue grew 8.97% YoY to $5.527 billion, with sequential quarterly revenue showing stability and slight acceleration. This indicates the core hospital and ambulatory care segments are driving steady top-line expansion.
Bearish
- High Financial Leverage: The debt-to-equity ratio of 3.12 indicates a highly leveraged balance sheet. This amplifies financial risk, particularly in a rising interest rate environment, and could constrain strategic flexibility.
- Severe Technical Downtrend and High Volatility: The stock is down 16.77% over the past month and has a beta of 1.495, making it ~50% more volatile than the market. It has retreated sharply from its 52-week high of $247.21, signaling a significant loss of momentum and elevated downside risk.
- Limited Analyst Coverage and Visibility: Only three analysts provide estimates, indicating selective institutional interest and potentially less efficient price discovery. The lack of a consensus price target makes it difficult to gauge the market's forward-looking conviction.
- Valuation at Upper End of Historical Range: The trailing P/E of 12.83x sits in the mid-to-upper end of its recent historical normalized range (7.81x to 16.56x). This leaves limited room for multiple expansion and increases vulnerability to a valuation de-rating if growth disappoints.
THC Technical Analysis
The stock is in a pronounced downtrend from its recent peak, with a 1-year price change of +53.11% indicating a strong longer-term uptrend, but the current price of $195.24 sits at the 65% level of its 52-week range ($109.82 to $247.21), having retreated significantly from the high. This positioning suggests the momentum has stalled, and the stock is consolidating after a major rally, with the risk of a deeper correction if key support levels fail. Recent momentum is decisively negative, with the stock down 16.77% over the past month and 2.96% over the past three months, a sharp reversal from the positive 1-year trend; this divergence signals a significant loss of bullish momentum, likely driven by profit-taking and sector rotation, with the stock's relative strength versus the SPY down 17.23% over the same period. Key technical support is the 52-week low of $109.82, while immediate resistance is the recent high of $247.21; a breakdown below the recent March low near $188 could signal a test of lower support levels, while a recovery above the $240 area is needed to restore the uptrend. The stock's beta of 1.495 indicates it is approximately 50% more volatile than the broader market, which amplifies both upside and downside moves and is a critical factor for risk-aware investors.
Beta
1.50
1.50x market volatility
Max Drawdown
-23.2%
Largest decline past year
52-Week Range
$110-$247
Price range past year
Annual Return
+57.4%
Cumulative gain past year
| Period | THC Return | S&P 500 |
|---|---|---|
| 1m | -13.6% | +4.9% |
| 3m | +0.7% | +0.6% |
| 6m | -1.3% | +5.1% |
| 1y | +57.4% | +28.8% |
| ytd | -1.4% | +1.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
THC Fundamental Analysis
Revenue growth remains positive but has moderated, with Q4 2025 revenue of $5.527 billion representing an 8.97% year-over-year increase; however, sequential quarterly revenue from Q1 to Q4 2025 shows a pattern of $5.223B, $5.271B, $5.289B, and $5.527B, indicating stable to slightly accelerating growth in the latter part of the year, driven by its core hospital and ambulatory care segments. The company is solidly profitable, with Q4 2025 net income of $371 million and a net margin of 6.70%, supported by a gross margin of 41.52%; profitability has been consistent, with net income figures of $406M, $288M, $342M, and $371M across the four quarters of 2025, demonstrating resilient earnings power despite industry cost pressures. The balance sheet carries significant leverage with a debt-to-equity ratio of 3.12, but liquidity is adequate with a current ratio of 1.76; the company generated substantial free cash flow of $2.53 billion over the trailing twelve months and an operating cash flow of $731 million in Q4 2025, providing internal funding for growth and debt service, though the high debt load remains a key financial risk to monitor.
Quarterly Revenue
$5.5B
2025-12
Revenue YoY Growth
+0.08%
YoY Comparison
Gross Margin
+0.41%
Latest Quarter
Free Cash Flow
$2.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is THC Overvalued?
Given the positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is 12.83x, while the forward PE is 11.12x, indicating the market expects modest earnings growth, as the forward multiple is slightly lower. Compared to sector averages, the stock's trailing PE of 12.83x appears reasonable for a healthcare services company, though a direct industry average is not provided in the data; its Price-to-Sales ratio of 0.85x and EV/EBITDA of 6.59x suggest the market is valuing the company's cash flow and sales efficiently relative to its enterprise value. Historically, the stock's own trailing PE has fluctuated significantly, from as low as 1.21x in Q1 2024 (an outlier due to a one-time gain) to a more normalized range between 7.81x and 16.56x over the past few years; the current multiple of 12.83x sits in the mid-to-upper end of this recent historical range, suggesting the market is pricing in steady performance but not excessive optimism, leaving room for multiple expansion if growth accelerates.
PE
12.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 1x~37x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
6.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is the company's high leverage, with a debt-to-equity ratio of 3.12. While strong free cash flow of $2.53 billion TTM provides a cushion for debt service, a sustained period of rising interest rates or an operational setback could pressure its ability to manage this debt load efficiently. Furthermore, the net margin, while positive at 6.70%, shows some quarterly volatility (ranging from 5.5% to 7.8% in 2025), indicating sensitivity to cost pressures common in the healthcare sector, such as labor expenses.
Market & Competitive Risks: THC faces significant market risk due to its high beta of 1.495, meaning it is likely to experience amplified moves during broader market sell-offs, as evidenced by its 17% underperformance versus the SPY over the past month. Valuation compression is a tangible threat, as its trailing P/E of 12.83x is at the upper end of its recent historical range, leaving it vulnerable to de-rating if growth expectations moderate. Competitive and regulatory pressures in the healthcare facilities industry could also constrain pricing power and margin expansion.
Worst-Case Scenario: The worst-case scenario involves a combination of a broader market downturn, a sector-specific regulatory crackdown or reimbursement pressure, and a quarterly earnings miss. This could trigger a rapid de-leveraging of its valuation multiple and a flight from high-beta stocks. The realistic downside could see the stock retesting its 52-week low of $109.82, which represents a potential loss of approximately -44% from the current price of $195.24. A more immediate bear-case target could be the recent technical support near $188, a breakdown of which could lead to a swift move toward the $160-$170 range.
FAQ
The key risks are, in order of severity: 1) Financial Risk: High leverage with a debt-to-equity ratio of 3.12, which increases vulnerability to rising rates and economic downturns. 2) Market Risk: Exceptional volatility, with a beta of 1.495, meaning the stock will likely fall more than the market in a downturn, as seen in its 17% one-month underperformance. 3) Operational/Sector Risk: Exposure to healthcare sector cost pressures (labor, supplies) which could compress its 6.7% net margin. 4) Liquidity/Visibility Risk: Limited analyst coverage (only 3 analysts) can lead to sharp price moves on news and less efficient price discovery.
The 12-month forecast is framed by three scenarios with associated probabilities. The Base Case (60% probability) sees the stock trading between $195 and $215, reflecting range-bound consolidation. The Bull Case (25% probability) targets a return to the $240-$247 range on successful debt reduction and sector recovery. The Bear Case (15% probability) warns of a decline to the $160-$188 range if operational pressures mount and high beta drives a sell-off. The Base Case is most likely, predicated on the assumption that the company's strong cash flow will prevent a fundamental collapse, but high leverage will cap significant multiple expansion in the near term.
Based on the provided data, THC appears fairly valued. Its forward P/E of 11.12x and EV/EBITDA of 6.59x are not excessive for a profitable healthcare services company. However, its trailing P/E of 12.83x sits in the mid-to-upper end of its own recent historical range (7.81x to 16.56x), suggesting the market is not offering a discount. The Price-to-Sales ratio of 0.85x indicates the market values its revenue stream efficiently. The valuation implies the market expects steady, low-to-mid single-digit earnings growth but is applying a discount for the company's financial leverage and sector pressures.
THC is a complex stock that may be a good buy for a specific type of investor. For a risk-tolerant investor seeking exposure to a cash-generative healthcare operator at a reasonable valuation (forward P/E of 11.12x), the current pullback could present an opportunity. However, the high debt load (D/E of 3.12) and extreme volatility (beta of 1.495) make it unsuitable for conservative portfolios. The lack of a clear analyst price target consensus adds to the uncertainty. It is a good buy only under the condition that the investor has a high risk tolerance and a conviction that the company's strong free cash flow will ultimately overcome its balance sheet risks.
THC is more suitable for a medium- to long-term investment horizon, with a suggested minimum holding period of 2-3 years. Its high beta (1.495) and recent severe downtrend make it a poor candidate for short-term trading, as volatility can quickly erase gains. A longer horizon allows time for the company's free cash flow to be deployed toward debt reduction, which could be a key catalyst for multiple expansion. The stock does not pay a dividend, so the total return is dependent on price appreciation. Therefore, only investors with the patience to wait for a fundamental deleveraging story to play out should consider a position.